AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Shore Capital in a report issued on Wednesday, ThisIsMoney.Co.Uk reports.
Several other research analysts also recently weighed in on AZN. Citigroup reaffirmed a “buy” rating and set a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research note on Wednesday, September 11th. Jefferies Financial Group increased their price objective on AstraZeneca from GBX 6,550 ($85.59) to GBX 6,700 ($87.55) and gave the company a “hold” rating in a research note on Tuesday, October 15th. UBS Group reissued a “sell” rating on shares of AstraZeneca in a research note on Monday, September 30th. Bank of America reissued a “buy” rating and issued a GBX 8,500 ($111.07) price objective on shares of AstraZeneca in a research note on Tuesday, October 8th. Finally, Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and a consensus price target of GBX 7,137.81 ($93.27).
Shares of AZN stock opened at GBX 6,803 ($88.89) on Wednesday. The company has a debt-to-equity ratio of 144.48, a current ratio of 0.95 and a quick ratio of 0.74. The company has a market cap of $89.23 billion and a price-to-earnings ratio of 39.74. The stock has a 50 day simple moving average of GBX 7,066.01 and a 200-day simple moving average of GBX 6,532.84. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 8,227.88 ($107.51).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.